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The eye and the brain are prototypical tissues manifesting immune privilege (IP) in which
immune responses to foreign antigens, particularly alloantigens are suppressed, and even
completely inhibited. Explanations for this phenomenon are numerous and mostly reﬂect
our evolving understanding of the molecular and cellular processes underpinning immuno-
logical responses generally. IP is now viewed as a property of many tissues and the level
of expression of IP varies not only with the tissue but with the nature of the foreign antigen
and changes in the limited conditions under which privilege can operate as a mechanism of
immunological tolerance. As a result, IP functions normally as a homeostatic mechanism
preserving normal function in tissues, particularly those with highly specialized function
and limited capacity for renewal such as the eye and brain. However, IP is relatively easily
bypassed in the face of a sufﬁciently strong immunological response, and the privileged
tissues may be at greater risk of collateral damage because its natural defenses are more
easily breached than in a fully immunocompetent tissue which rapidly rejects foreign anti-
gen and restores integrity. This two-edged sword cuts its swathe through the eye: under
most circumstances, IP mechanisms such as blood–ocular barriers, intraocular immune
modulators, induction of T regulatory cells, lack of lymphatics, and other properties main-
tain tissue integrity; however, when these are breached, various degrees of tissue damage
occur from severe tissue destruction in retinal viral infections and other forms of uveoreti-
nal inﬂammation, to less severe inﬂammatory responses in conditions such as macular
degeneration. Conversely, ocular IP and tumor-related IP can combine to permit extensive
tumor growth and increased risk of metastasis thus threatening the survival of the host.
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INTRODUCTION
The ﬁrst Ophthalmology textbook in English, written in the ﬁrst
half of the nineteenth century, contained a description of sym-
pathetic ophthalmia (SO), an intraocular inﬂammatory disease
which develops in the fellow eye several months after penetrating
injury to the ﬁrst eye (Mackenzie, 1830). SO was a pre-eminent
example of “horror autotoxicus” (reviewed in Mackay, 2010) and
the search was on to deﬁne the autoantigen(s) (Faure, 1980),many
of which are located in the retina (Wacker, 1991). At the same
time as immunity and autoimmunity were being recognized, the
remarkable acceptance of corneal allografts compared to skin allo-
grafts (ZIrm, 1906), which had been reported in the early part of
the twentieth century, allowed Medawar to formulate the con-
cept of immune privilege (IP). IP was a property of certain tissues
(speciﬁcally the eye and the brain; Medawar, 1961) in which for-
eign antigens placed in those tissues failed to evoke a conventional
immune response. Such tissues were seen to be afforded a level of
protection from immunological damage (termed IP).
The concept of IP has since been extended and is now regarded
as a relative term, not unique to the eye or brain; it is a property
of many tissues, develops de novo in accepted vascularized grafts
(Cobbold, 2009; Huang et al., 2010) and constitutes part of the
immune response to tumors (Mellor and Munn, 2008). Ocular IP
is inducible and transferable (through adoptive transfer of CD8+
T regulatory cells (Tregs) — infectious tolerance; Grifﬁth et al.,
2011) and thus has informed immunology generally on regulatory
mechanisms.
Despite ocular IP, autoimmune and immune-mediated diseases
of the eye occur with demoralizing frequency; for instance, 5 year
survival rates of corneal allografts in humans are lower than those
of solid organ grafts (Williams and Coster, 1997), although this
statistic can be somewhat misleading since most corneal allografts
in humans are performed without tissue matching (see below);
also, both innate and adaptive immune mechanisms underlie
several blinding ocular diseases, the scourge of populations word-
wide, such as age-related macular degeneration (AMD), infectious
corneal blindness, glaucoma and the “Cinderella” disease, uveitis
(see Box 1).
Ocular IP has been reviewed several times recently (Caspi,
2006; Niederkorn, 2006; Ferguson and Grifﬁth, 2007; Forrester
et al., 2008b). This review therefore will focus on the place
of IP as an immunoregulatory, tolerance-inducing mechanism,
and discuss its limitations in the context of sight-threatening
diseases.
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Box 1 | Uveitis.
Terminology for Uveitis is confusing and as a result the condition
has been somewhat neglected as a global cause of blindness (thus
it is a “Cinderella” syndrome) mainly because clinicians have had
difﬁculty reaching agreement as to what constitutes uveitis. How-
ever, a recent initiative is aimed at developing international criteria
for the various entities that come under the umbrella of uveitis
(Standardization of Uveitis Nomenclature, SUN; Jabs et al., 2005).
The term “Uveitis” is a misnomer since it suggests that the
focus of inﬂammation is the uvea. Discrete parts of the uvea can be
affected separately: the iris (iritis), ciliary body (cyclitis, iridocyclitis),
choroid (choroiditis), or entire uvea (panuveitis; see Figures 1A,B).
However, the triggering antigens (either foreign or self-antigens
from retina, lens, cornea) can be located in any of the tissues,
including the uveal tract itself. The most potent autoantigens have
been identiﬁed in the retinal photoreceptors. Accordingly, uveitis
(uveoretinitis) is also classiﬁed under the term “Intraocular Inﬂam-
mation,” and sub-classiﬁed as to whether it affects the anterior
segment of the eye (“anterior segment intraocular inﬂammation,”
ASII) in which it is restricted to the cornea, anterior chamber, iris,
ciliary body, and lens, or it selectively affects the posterior segment,
which includes the pars plana region of the ciliary body (pars plani-
tis), the vitreous gel (vitritis), the retina (retinitis), the retinal vessels
(retinal vasculitis), the choroid (choroiditis), or the optic nerve (papil-
litis, optic neuritis; posterior segment intraocular inﬂammation,
PSII).
Uveitis according to the SUN criteria is classiﬁed by its underlying
cause and then according to its anatomic location (Table 1).
Table 1 | Classification of uveitis (SUN criteria) with some examples.
Classification Type of uveitis/uveoretinitis/intraocular inflammation
Infectious Non-infectious
Anterior Viruses HLA B27-associated uveitis
e.g., HSV, CMV, VZV
Intermediate Toxocara Pars planitis
Toxoplasmosis Idiopathic vitritis
Intermediate uveitis
Posterior Toxoplasmosis Retinal vasculitis
Tuberculosis Multifocal choroiditis
Syphilis PIC*
Lyme disease Behcet’s disease
Candida Vogt–Koyanagi–Harada disease
Panuveitis All of above All of above
*PIC, punctate inner choroidopathy, a chronic low grade inﬂammation with
subretinal neovascularization (see text).
IMMUNOLOGICAL PROPERTIES OF THE EYE
CELLS AND TISSUES
Several ocular tissues such as the uvea (middle layer of the eye
comprising the iris, ciliary body, and choroid), the cornea, the
conjunctiva, and periocular fascia (Forrester et al., 2008a; see
Figure 1), contain rich networks of innate immune cells (bone
marrow-derived resident macrophages and dendritic cells, DCs)
which, together with the parenchymal cells, secrete a wide range
of mediators which underpin IP (Forrester et al., 2008b, 2010).
The retina contains specialized myeloid cells (microglia), similar
to brain microglia, recently reported to originate from yolk sac
precursors (Ginhoux et al., 2010). In addition, the central (around
the optic nerve) and peripheral (at pars plana, Figure 1) rims of
the retina contain a small population of DCIR+ MHC Class IIhi
DCs, as does the corneal periphery (Xu et al., 2007b).
Recently, a small population of retinal DCs has been described
in mice expressing CD11c-GFP (Heuss et al., 2012) although the
speciﬁcity of CD11c for DCs is open to question. The central
cornea has few DCs but contains MHC Class II+ macrophages
(Brissette-Storkus et al., 2002; Sosnova et al., 2005; Kuffová et al.,
2008) while peripheral corneal epithelial Langerhans cells and
stromal Langerin+ cells also reside in the cornea (Hattori et al.,
2012). The lens contains no myeloid cells while the normal
extravascular tissue of the eye is devoid T or B cells.
BLOOD–OCULAR BARRIERS
The intraocular compartments (Figure 1B) are separated from the
blood and lymphatic circulations by the blood–aqueous barrier
and the blood–retinal barrier (BRB; Forrester et al., 2008a).
Blood–aqueous barrier
Blood–aqueous barrier has two components – tight junctions
between the endothelial cells of the ciliary blood vessels and sim-
ilar junctions between the lining epithelial cells (Figure 1). The
epithelial cells of the ciliary body maintain the intraocular pres-
sure by pumping ﬂuid which drains through the porous trabecular
meshwork of the anterior chamber into the blood and lymphatic
vessels of the episclera (Figure 1B). The sclera itself, like the central
cornea, is avascular.
Blood–retinal barrier
Blood–retinal barrier also comprises two components — tight
junctions of the retinal vessels and of the retinal pigment epithe-
lium (RPE; Figure 2). The RPE is a terminally differentiated layer
of neuroectoderm-derived cells formed embryologically by cells of
the developing outer layer of the optic cup (Kim and Kim, 2012)
whose function is tomaintain the physiology of the photoreceptors
and remove waste products (see below).
OCULAR CONNECTIONS TO SECONDARY LYMPHOID
TISSUES
Although the periocular tissues such as the conjunctiva and
the episclera (see Figure 1) contain lymphatics, the intraocular
compartment of the eye lacks traditional lymphatics. Aqueous
ﬂuid from the anterior chamber, presumably containing soluble
antigen shed physiologically, drains via episcleral blood vessels
(aqueous veins) through the venous circulation to thymus, liver,
and spleen (Figure 3). There is also a site-speciﬁc eye-draining
lymphnode (DLN)which receives soluble and cell-associated anti-
genic material from the eye (Plskova et al., 2002; Kuffová et al.,
2008). Fluid also tracks by transscleral ﬂow from the vitreous
cavity across the retina driven by a RPE Na+K+ ATPase pump
which, when damaged, causes subretinal ﬂuid accumulation (For-
rester et al., 1990), but the likelihood of shed ocular antigens
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FIGURE 1 | Anatomy/physiology of the eye to include ocular immune
cells. (A)The eye is composed of three layers: an outer layer (cornea/sclera),
an inner layer (retina), and a middle layer (uvea, a continuous structure
comprising iris, ciliary body, and choroid). The anterior chamber lies between
the iris and the cornea, the posterior chamber between the lens and the iris,
and the vitreous cavity (containing the vitreous gel, a type II/XI collagenous
avascular extracellular matrix) describes the main chamber of the eye behind
the lens. The human eye maintains a pressure between 10 and 20 mm Hg,
which is generated by the unidirectional ﬂow of ﬂuid (aqueous humor
secreted by the ciliary body) from the posterior chamber into the anterior
chamber, and leaving the eye via the trabecular meshwork, to drain into the
episcleral veins. The “fundus oculi” is the view of the retina/choroid seen
through the ophthalmoscope; the central fovea/macula is a cone
photoreceptor-rich area, 500 microns in diameter, subserving central visual
acuity. The remaining retina provides peripheral vision (visual ﬁeld) and all
visual information is transmitted through retinal neuronal cells, via the optic
nerve, which synapse in the lateral geniculate body intracranially. The uvea
contains a network of resident innate immune cells (DCs and macrophages)
and is highly vascular (seen in section and en face views in the ﬁgure). The
retina contains few conventional resident myeloid cells, but has a population
of microglial cells (see text). Normal ocular tissues are devoid of
lymphocytes. The cornea contains a population of passenger leukocytes
mostly in its peripheral rim as well as some lymphatics in this region
connecting with lymphatics in the conjunctiva. (B) Eye health is dependent on
having a normal intraocular pressure, which is maintained between 12 and
20 mm Hg by the ﬂow of aqueous ﬂuid from the posterior chamber of the eye
(the space between the posterior surface of the iris and the anterior surface
of the lens) and the anterior chamber (the space between the posterior
surface of the cornea and the anterior surface of the iris). The vitreous cavity
is the intraocular compartment behind the lens and in front of the retina.
Aqueous ﬂuid is secreted by the epithelial cells of the ciliary body into the
posterior chamber and ﬂows through the pupil of the iris into the anterior
chamber to drain through the trabecular meshwork at the angle of the eye
between the iris and the cornea, into the subconjunctival space, to be ﬁnally
removed by interstitial ﬂuid ﬂow into the episcleral veins and the
subconjunctival lymphatics.
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FIGURE 2 | Blood–retinal barrier (BRB).The BRB is created by tight
junctions at two sites: between endothelial cells of the retinal vessels that
supply the inner retina (ganglion cells and bipolar cells) and the retinal
pigment epithelium (RPE cell; which ﬁlters blood from the fenestrated, leaky
choroidal vessels). The RPE regulates two-way transport of ﬂuid, nutrients,
and waste between the outer retina (photoreceptors) and the fast ﬂowing,
high volume choroidal bloodstream. The choroid stroma contains resident
innate immune cells to maintain homeostasis in the outer retina (see
Forrester et al., 2010) as well as ﬁbroblasts and melanocytes. Breakdown of
the BRB can thus occur either at the retina vessels or at the RPE layer.
reaching lymphatics through this route is low, given the extremely
high ﬂow rates of blood through the choroidal vessels (Forrester
et al., 2008a).
NEURAL CONNECTIONS
Aside from the neural connections to the brain via the visual
pathways, for which there are several types of photoreceptors,
as well as light-sensitive melanopsin-containing neurons gener-
ating circadian rhythms (Do and Yau, 2010), the eye has a full
complement of motor, sensory, and autonomic nerves. Some
provide, or respond to, immunoregulatory moieties with IP-
promoting properties, including the neuropeptides,αMSH,CGRP
and VIP, PACAP, melanocortin and retinoids (reviewed in For-
rester et al., 2008b). Others provide routes for immune attack
and evasion as in herpes virus infection of the cornea (via the
Vth cranial nerve). CD8 T cells have a unique role in maintain-
ing HSV latency at the trigeminal ganglion (Sheridan et al., 2007;
Frank et al., 2012).
THE HAZARDOUS NATURE OF OCULAR IMMUNE PRIVILEGE
The term IP was coined to indicate that certain tissues or cells have
an advantage over others, allowing them to modulate immune
responses to foreign antigens or to be regarded themselves as non-
immunogenic when transplanted (e.g., stem cells; Robertson et al.,
2007; Zhou and Caspi, 2010). However, IP as such carries risks to
the host since it permits foreign antigens/organisms to “hide” in
IP sites (Wekerle, 2006).
WHAT IS IMMUNE PRIVILEGE?
Different levels of IP apply to many tissues, including some which
are normally expected to mount full blown immune responses
to foreign antigens (skin, lung, and gut). Conceptual shifts in
the self/non-self paradigm underpinning adaptive immunity have
emerged from evidence that innate immune recognition of foreign
antigens has some degree of speciﬁcity [via pathogen-associated
molecular patterns (PAMPs) and pathogen recognition receptors
(PRRs; Kumar et al., 2011)]. This idea has evolved beyond selective
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FIGURE 3 | Circulation of immune cells to and from the eye. Myeloid cells
(macrophages and DCs) trafﬁc from the bone marrow to the eye via the blood
and populate some ocular tissues, predominantly the uvea (iris, ciliary body,
and choroid); a few cells enter the peripheral retina and cornea.When ocular
tissues are perturbed, bone marrow-derived cells, carrying antigen from the
eye, can be found in the eye-draining lymph node (DLN; see text). However
whether there is transport of steady-state antigen to the DLN is not known.
Both cell-associated and soluble antigen injected into the eye, or applied to
the abraded cornea, can be detected in the spleen after several hours.
RestingT and B cells circulate normally through the uveal blood vessels of
eye but do not cross the blood–ocular barriers; it is presumed they
communicate with eye-derived antigen presenting cells in the secondary
lymphoid tissues (spleen and lymph node) and respond appropriately to
promote tolerance or immunity as in other tissues (see text).
recognition of pathogens, to recognition of “Danger” by the host
(Matzinger, 2001; Miller et al., 2011), and to the notion that differ-
ent tissues contribute variably to immune regulation particularly
of the effector response, depending on which speciﬁc structures or
functions are threatened (Matzinger, 2007; Matzinger andKamala,
2011). While the Danger hypothesis has greatly broadened our
understanding of how immunological responses are initiated, a
certain caution might be exercised since it is difﬁcult to deﬁne
“Danger” in molecular or cellular terms. Accordingly, since IP
itself as a concept is contingent upon the self/non-self paradigm
of adaptive immunity, it is timely to review exactly what IP
means.
At its core, IP is a form of tolerance expressed through tissue-
speciﬁc properties (see above), is shown to be inducible toward
foreign and alloantigens, and is assumed to underpin tolerance
to ocular self-antigens. As a general hypothesis therefore, we can
consider tissue-centered immunological tolerance as additional to
the well-established central and peripheral tolerance mechanisms
(Matzinger, 2007). Tissue-centered tolerance (TCT; Matzinger
and Kamala, 2011) varies with the nature, properties, and vas-
cularity of the tissue and is optimal in tissues such as eye and
brain. In other tissues, TCT or IP can be induced, for instance
as in accepted allografts and even in the stem cell niche (Robert-
son et al., 2007; Cobbold, 2009; Waldmann, 2010; Fujisaki et al.,
2011). Interestingly, in these environments Treg induction seems
to be the main mechanism of immune tolerance. As such, tis-
sues which depend on their intrinsic properties for immunological
protection or privilege (IP) are at greatest risk when tolerance is
breached.
Several mechanisms are proposed to explain ocular IP includ-
ing sequestration of antigen from the developing immune system
behind blood–ocular barriers (immunological ignorance), lack of
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lymphatics, absence of MHC Class II+ professional antigen pre-
senting cells (APCs; Hamrah andDana, 2007; Forrester et al., 2010;
negates CD4 T cells), lack of expression of MHC Class I on tis-
sue cells (negates CD8 T cells), expression of Qa-1 and HLA-G/E
(negates NK cells), presence of immune modulators such as TGFβ,
CD200, CD55, and CD46, decay-acceleration factor (DAF; mod-
iﬁes APCs), and lack of thymic expression of tissue antigens (no
autoreactive T cells to escape to the periphery; Forrester et al.,
2008b; Zhou and Caspi, 2010).
In addition, parenchymal cells of the eye have the capacity,
at least in vitro, to exert T cell suppressive activity (Caspi et al.,
1987; Ferguson and Grifﬁth, 2007) as well as generate Tregs (Tay-
lor et al., 1997; Yoshida et al., 2000; Zamiri et al., 2007; Sugita et al.,
2010). Expression of molecules such as FasL (Ferguson and Grif-
ﬁth, 2007), PDL1 (Usui et al., 2008), CTLA4 (Sugita et al., 2006),
and the recently described CTLA2 (Sugita et al., 2008) by ocular
cells particularly the iris, ciliary body, and RPE cells generate
an immunosuppressivemicroenvironment (Stein-Streilein, 2008).
The PD-1 pathway is interesting since it appears to have the capac-
ity to promote T effector cell death similar to the Fas/FasL pathway,
but also has the potential to promote Tregs (Francisco et al., 2010).
Recently, retinoids (speciﬁcally retinoic acid, RA) have been impli-
cated in the induction of Tregs by the RPE in vitro (Kawazoe et al.,
2012). RA produced by CD103+ lamina propria DCs has been
identiﬁed as a major inducer of intestinal Tregs and this property
of DCs has been extended to non-intestinal DCs (for review, see
Nagy et al., 2012). In these conditions, the Treg-inducing effects
of RA required TGFβ (Cong et al., 2009). Recent data showed
that vitamin A-deﬁcient mice were unable to convert naïve T cells
to Tregs in the uninﬂamed eye in vivo which was interpreted as
being due to an absence of locally produced RA, presumably by
intraocular DCs (Zhou et al., 2012). However, in conditions of
active experimental autoimmune uveoretinitis (EAU), commit-
ted T effector cells could not be converted to Tregs suggesting
that this component of IP was lost during inﬂammation. Previous
studies had, in fact, shown that RA promoted the immunogenic-
ity of DCs in a pro-inﬂammatory environment (Geissmann et al.,
2003) and this may explain the results from the above experiment
in uveitis.
A potential role of RA in IP in the eye is a logical conceptual
extension given the role and high concentrations of retinoids in
the visual cycle. The RPE speciﬁcally expresses one of the enzymes
(RALDh10) required for metabolizing retinal (vitamin A) to RA,
and all-trans retinal itself has recently been shown to induce Tregs
in vitro (Jeon et al., 2012). However, most of the retinoids in the
RPE, if not used in the visual cycle, are stored as inactive retinyl
esters, and are converted to retinal by RALDh10 if vitamin A
blood levels decline. In vivo evidence that visual cycle retinoids
themselves participate in IP is lacking, probably because their
escape from the visual cycle is tightly regulated. Indeed it has
been shown that accumulation of all-trans-retinal in mice lack-
ing the ABCA4 transporter (ATP-binding cassette transporter 4)
and RDH8 (retinol dehydrogenase 8) are liable to retinal degen-
eration, particularly that induced by light (Maeda et al., 2009).
However, there are large networks of ocular tissue-resident DC
which are likely to be a source of retinoids for Treg induction
(Forrester et al., 2010). Indeed this may be a universal property
of all tissues related to tissue-resident, homeostasis-promoting,
self-tolerizing DCs, which is dependent on the density and pheno-
type of the DC, and is at a high level in the eye. Interestingly,
Tregs are important for maintaining IP in the brain and they
maintain this function even in the face of acute viral encephalitis,
thus minimizing bystander damage and presumably preventing
autoimmunity associated with the viral infection (Cervantes-
Barragan et al., 2012). Induction of Tregs by DC in allografts
and other sites has been described as a form of acquired IP and
has been attributed in part to the expression of indoleamine
oxidase (IDO; for review, see Huang et al., 2010; Kushwah and
Hu, 2011) probably underscoring the fact that there are multi-
ple potential routes for induction of Tregs, but more importantly
highlighting the link between IP and Treg induction. Interest-
ingly, RA- and TGFβ-mediated Treg induction does not carry over
to IL-10 Tr1 regulatory cell induction, in which these molecules
do not have any effect and may in fact have a negative role
(Maynard et al., 2009).
HowTregsmightmediate privilege is unclear. Micewith defects
in central tolerance (such as those deﬁcient in the autoimmune
regulator geneAire required for negative selection of certain tissue-
speciﬁc antigens presented by mTECs) develop mild to moderate
ocular inﬂammation as part of a multiple autoimmune diathesis
(Anderson et al., 2002; DeVoss et al., 2006). However, Aire is also
involved in induction of natural Tregs in the thymus (Aschenbren-
ner et al., 2007) and Aire has also been detected in the periphery,
both factors indicating that this gene probably does not have a
restricted role in central tolerance (Metzger and Anderson, 2011).
Mice with deﬁned immunodeﬁciencies involving Tregs are not
known to have ocular pathology which would suggest that either
Tregs do not contribute to ocular IP or that tissue-centered “IP-
like” mechanisms (TCT) are sufﬁcient to sustain tolerance in
the eye. This has however, to our knowledge, not been directly
tested in Treg-deﬁcient mice, using conventional models of ocular
autoimmunity, such as EAU. Despite this, patients with uveitis are
reported to have decreased levels of circulating Tregs which sug-
gests that peripheral tolerance, if not IP, is necessary to maintain
immunological homeostasis. Tregs occur as part of the inﬁltrat-
ing inﬂammatory cell population in the retina in EAU, indicating
that they almost certainly play a role. Since TCT is one aspect
of tolerance generally, it may be somewhat semantic to attribute
exclusivity in these mechanisms.
It can be seen that there are many possible mechanisms which
explain the immunosuppressive properties of the eye associated
with IP, all of which have been shown to be only partially vali-
dated, if functional at all in vivo; moreover, one single mechanism
is unlikely to account fully for ocular IP; instead, each probably
contributes to overall immune homeostasis. In this context, the
eye’s IP properties offer strong supportive evidence forMatzinger’s
TCT hypothesis but as discussed below, in many circumstances
IP/TCT is insufﬁcient to fully protect the eye from Danger.
DOES IP HAVE MEMORY?
Adaptive immune responses to foreign antigens are characterized
by memory. Tolerance to self-antigen involves antigen-speciﬁc
responses leading to deletion, peripheral anergy, and/or regulation
with memory. Tolerance operates when there is risk of self-antigen
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exposure to the immune system, for instance during apoptotic
turnover of cells, by processes which suppress immune-mediated
inﬂammation and encourage “silent” clearance of cellular debris.
Much of this activity is conducted in secondary lymphoid tissues
like the liver and spleen, which drain the interstitial ﬂuids via
lymphatic and blood circulations.
Tolerance to nominal antigens is demonstrable when, after
exposing the organism to antigen, an immune response to that
antigen cannot be induced on re-challenge. In some circum-
stances, an immune response can be elicited on re-challenge but
is attenuated or modiﬁed: the latter circumstance is known as
immune deviation. Tolerance is an active process involving T cell
proliferation followed by apoptosis (activation-induced cell death,
AICD) and clearance of cell debris by resident tissue scavenger
cells. However, if the initial encounter with antigen involves cell
necrosis and/or“adjuvant”effects of microorganisms via PRRacti-
vation and induction of IL-1/IL-18 via the inﬂammasome or other
mechanisms (van de Veerdonk et al., 2011), an active pathogenic
immune response with concomitant inﬂammation and bystander
tissue damage may occur.
There are several routes of antigen (Ag) administration for
inducing tolerance: intravenous (iv), subcutaneous (s/c), mucosal
(oral/nasal/conjunctival), intraperitoneal (ip), and intraocular
(io). Io injection involves antigen uptake by APC (Dullforce
et al., 2004) and induction of antigen-speciﬁc T cells, followed
by T cell and APC apoptosis via Fas/FasL (Green and Ferguson,
2001). Systemic tolerance to that antigen can then be demon-
strated by antigen re-challenge in a delayed-type hypersensitivity
(DTH) skin test (as originally shown for alloantigens by Medawar,
1948). This response is antigen-speciﬁc and thus has “memory,”
requires a minimum period of 3 days to develop, and is depen-
dent on an intact oculo-splenic axis (Streilein and Niederkorn,
1981). The tolerizing effect can be transferred to naïve mice by
serum (Grifﬁth et al., 1995), and by circulating mononuclear cells
(PBMC; Wilbanks and Streilein, 1992), from mice injected io with
antigen some days previously. Some of these PBMC express the
F4/80 antigen (Wilbanks and Streilein, 1992).
Trafﬁcking studies using tagged molecules in mice injected io,
or after application to the abraded cornea, indicate that soluble
antigen rapidly reaches the eye-DLN within 30 min (Camelo et al.,
2004, 2006) and then circulates widely to other lymph nodes (LNs;
including the mesenteric) and to the spleen within several hours.
Cell-associated antigen, after injection into the anterior cham-
ber, can be detected in the DLN at 6 h, and in the spleen after
16–24 h indicating that cellular trafﬁc from the eye to these sites
is possible (Kuffová et al., 2008). However, data from experiments
which involve intraocular injection require cautious interpretation
since io penetration necessarily involves some backﬂow of antigen
from the eye directly into the blood and lymphatic circulations
(see below).
Irrespective of how the antigen reaches the spleen, i.e., as
soluble, or later as cell-associated antigen, most groups agree
that DTH-testable antigen-speciﬁc tolerance can be transferred
to naïve mice by splenic CD8+ Tregs from mice injected io with
antigen. The nature of the APC which promotes this tolerance
is unclear, but mice deﬁcient in cells expressing the macrophage
surface marker F4/80, fail to generate tolerance after io injection
(Lin et al., 2005). Intuitively, however, it is unlikely that cells from
the eye directly mediate this effect since the number of ocular
F4/80+ cells is limited; furthermore, previous studies failed to
demonstrate APC migration from the iris after io antigen admin-
istration (Dullforce et al., 2004). An alternative possibility is that
ocular ﬂuids, perhaps containing material shed as microparti-
cles or exosomes, or more conventionally as soluble proteins,
from incoming inﬂammatory cells (including T cells undergoing
Fas/FasL-mediated apoptosis and expressing TRAIL or shedding
sTRAIL (Green andFerguson,2001; Grifﬁth et al., 2011)), enter the
blood circulation and arrive at the spleen where further ampliﬁca-
tion of the NKT cell/F4/80 spleen cell-mediated process of T cell
apoptosis occurs (Faunce and Stein-Streilein, 2002). Since toler-
ance via this route is transferable by serum and has been shown to
involve TCR components (Grifﬁth et al., 1995), a possible explana-
tion for T cell antigen speciﬁcity via cell surface particle shedding
in this model arises.
The main ﬂaw in these studies, going back to Medawar, is
that the technical procedure of inoculating antigens into the eye
causes breakdown of the blood–ocular barrier, however tran-
siently, with leakage of antigen into the periocular blood and
lymphatics, sufﬁcient to permit rapid tracking of antigen to the
spleen either directly via the blood or after a ﬁrst pass through
the DLN and thence to the spleen via the LN conduit system,
high endothelial venules (HEV) and efferent lymphatics (Plskova
et al., 2002; Kuffová et al., 2008). Tolerance induced by io injection
is therefore not, in substance, different from tolerance induced
by iv injection (antigen tracks directly to spleen), or by sc or ip
injection (antigen tracks via DLN to the spleen). Models which
suggest that TGFβ-treated F4/80+ peritoneal macrophages pref-
erentially mirror ocular IP overstate the case (Hara et al., 1992;
Niederkorn, 2009), and are probably not mechanistically different
from models of myeloid suppressor cell activity (Gabrilovich and
Nagaraj, 2009). Indeed, a recent study conﬁrmed the role of
splenic red pulp F4/80hiMac-1lo macrophages as immunosuppres-
sive cells and showed that they act by inducing CD4+CD25+
Tregs in a CSF-1-dependent manner (Kurotaki et al., 2011).
Gregerson et al. (2009) in an attempt to eliminate this techni-
cal ﬂaw, showed that CD4+CD25+ Treg-mediated tolerance to
endogenous retinal antigen, tested via retinal antigen-expressing
viral infection, was reduced when the source of retinal antigen
had been removed by enucleation of the eyes. However, the
trauma of enucleation is likely to induce a systemic concomi-
tant “Danger” signal which is difﬁcult to control for (Miller et al.,
2011; van de Veerdonk et al., 2011). In contrast, intact periph-
eral T cell anergy as well as CD4+CD25+ Treg generation (Lambe
et al., 2007) seemed necessary to avoid spontaneous uveitis in a
transgenic neoantigen model despite considerable central deletion
(Lambe et al., 2007).
The time differential for soluble antigen (minutes) vs cell-
associated antigen (hours) trafﬁcking from the eye or indeed from
any LN drainage site is important in the context of induction of
tolerance vs immunity. LN resident APC, which will preferentially
capture fast-tracking soluble antigen as it percolates along the con-
duits, present low levels of speciﬁc antigenic peptide–MHC Class
II (p-MHCII) complexes, while migratory DCs entering the DLN
several hours later present high levels of p-MHCII (Itano et al.,
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2003; Sixt et al., 2005). Both resident and migratory DCs have the
capacity to induce T cell proliferation, but only migratory DC,
through prolonged T cell/DC interactions, induce T cells which
mediate DTH (for review, see Catron et al., 2004). Thus the earlier
arrival of soluble antigen to the secondary lymphoid tissues will
promote tolerance rather than DTH-style T cell responses. This
underappreciated concept may explain many aspects of ocular IP
and the essential nature of the time-dependent oculo-splenic axis
since it may be indirectly accessed via rapid transit of “tolerizing”
antigenic signals by a ﬁrst pass through eye-DLN as well as directly
through the bloodstream.
SUBVERTING PRIVILEGE-PROMOTING CELLS
Despite the above caveats to what IP actually is and how it func-
tions, there is little doubt that the intraocularmicroenvironment is
immunomodulatory. Some of this is attributable to ocular-speciﬁc
cells such as the iris–ciliary body epithelium and the RPE as shown
inmany in vitro studies, throughmediators such asNO,PGE2, and
retinoids (Forrester et al., 2008b; see Immunological Properties of
the Eye). However, the microenvironment is altered by mediators
introduced, e.g., via a disruptedBRB.Cytokines such as IFNγ, gen-
erated systemically during viral infections, can activate RPE cells
to up-regulate immunosuppressive activity via PDL-1 (Ke et al.,
2010) or to produce pro-inﬂammatory chemokines and cytokines
locally, as well as induce MHC Class II expression on normally
negative RPE (Liversidge et al., 1988, 1994; Mesri et al., 1994) and
endothelial cells. Secretion of IL-6 by RPE cells in an environment
rich inTGFβ,may be sufﬁcient to convertCD4+ Tregs toTh17 cells
and completely alter the immunosuppressive microenvironment
to a pro-inﬂammatory one (Crane et al., 1999).
BREACHES OF PRIVILEGE
Immune privilege comes at a cost – if the privileged status of the
eye is compromised, the ensuing disease can be devastating (Caspi,
2006; Forrester et al., 2008b). Several ocular conditions occur in
which IP fails.
NON-INFECTIOUS INTRAOCULAR INFLAMMATION (UVEITIS)
Uveitis is a common disease (Darrell et al., 1962; Gritz and Wong,
2004; Williams et al., 2007) and comes in several varieties (Box 1).
Direct infectious uveitis is less common while non-infectious
uveitis is presumed to be (auto)immune in character. Despite
their low expression on ocular cells, certain forms of uveitis
have strong links with MHC Class I antigens (HLA B27: acute
anterior uveitis; HLA B51: Behcet’s disease; HLA A29: birdshot
retinochoroiditis; Levinson, 2007). Acute anterior uveitis may
be self-limiting, which has been attributed to Fas/FasL-induced
T cell apoptosis, demonstrating IP in action in human disease
(Dick et al., 1999).
Non-infectious uveitis is CD4+ T cell-mediated (Th1 and
Th17) in humans and mice (Amadi-Obi et al., 2007; Caspi, 2010).
Ocular tissues contain many potential autoantigenic targets, espe-
cially retina, apparently sequestered from the immune system
(Gregerson et al., 2009). Consequently, escape of antigen dur-
ing damage (trauma, infection, inherited degenerations) is one
route to activate rare autoreactive T cells in the periphery (Caspi,
2010). However, most uveitis occurs in virgin tissue, raising the
question: how do activated T cells cross the BRB? Systemic sig-
nals, from chemokines and other molecules, appear to “pre-
pare the way” across the endothelium (Xu et al., 2004, 2008;
Crane et al., 2006).
“Systemic signals”generated during infections, involvingmech-
anisms such as molecular mimicry and bystander activation
(Benoist and Mathis, 2001; Ji et al., 2010), do not disguise the fact
that, once activated, antigen-speciﬁc T cells enter the retina and
cornea with asmuch ease as into any tissue, accumulate in situ, and
attract pro-inﬂammatorymacrophageswhich cause tissue damage
(Forrester et al., 1998). In EAU, inﬂammation declines inversely
with an increase in CD4+CD25+FoxP3 Tregs, which accumulate
and promote resolution. However, EAU in the C57/BL6 mouse
does not completely resolve but persists with a macrophage-
mediated choroidoretinal angiogenic response (Chen et al., 2012)
much as occurs in some uncommon human uveitides (PIC, see
Box 1; Atan et al., 2011).
Spontaneous models of EAU more closely represent non-
infectious human disease, which occurs without a recognizable
trigger. Limited T cell anergy as well as possible antigen escape
from sequestration (immunological ignorance) have been sug-
gested to underpin breakdown of tolerance in this model (Lambe
et al., 2007; Gregerson et al., 2009). Interestingly, early cells enter-
ing the tissues in this model are IL-17-secreting γδ-like T cells
(Makinen, 2006), which have been implicated in the early patho-
genesis of conventional IRBP-induced EAU (Nian et al., 2011).
However, γδ T cells may have a regulatory role (Girardi and
Hayday, 2005; Pennington et al., 2005; Nian et al., 2010) as
well as a pathogenic role (Nian et al., 2011) in autoimmune
uveoretinitis.
Immune privilege appears not to afford much protection
against the damaging effects of uveitis possibly because IP works at
the level of tissuehomeostasis,mainly keepinghealthy tissue free of
random migrants which might provoke inﬂammation. However,
when faced with a serious challenge, IP dismally fails to prevent
severe destruction: in uncontrolled sight-threatening uveitis, both
infection and the immune response to infection, can cause per-
manent structural damage. Therapies such as anti-TNFα disable
the destructive effects of inﬂammation while permitting harm-
less monocytes to traverse the tissues without causing damage
(reviewed in Khera et al., 2010).
TRANSPLANTATION
Several types of ocular allografts are performed in humans,
including corneal, limbal (stem cells), scleral, and retinal grafts.
However, IP does not protect against allograft rejection: even
artiﬁcial corneas constructed from pig collagen, are rejected via
antibody-mediated mechanisms (Liu et al., 2007).
Corneal grafts
Despite a long-established reputation for high rates of acceptance,
long-term corneal graft survival rates actually lag behind vascu-
larized solid-organ grafts (Williams and Coster, 1997). Corneal
grafts in humans are normally performed without tissue match-
ing, and graft acceptance was historically attributed to the absence
of passenger leukocytes. However, as indicated above, corneal
tissue contains both resident MHC Class II+ macrophages and
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peripheral lymphatics (Brissette-Storkus et al., 2002; Sosnova
et al., 2005; Xu et al., 2007a; Ecoifﬁer et al., 2010). Despite the
presence of MHC Class I and II leukocytes in the donor cornea,
corneal graft rejection occurs at a slower tempo than comparably
unmatched solid-organ allografts indicating a degree of “privi-
lege”; in part this is due to the fact that corneal graft rejection is
mediated via indirect allorecognition, and direct alloresponses do
not contribute to this process (Boisgerault et al., 2009). Corneal
graft rejection thus resembles chronic indirect allorecognition of
vascularized grafts which is also of a considerably slower tempo,
is mediated by CD4 T cells, and is greatly accelerated when innate
immune activation is at high levels, e.g., in cases of infectious
or atopic ocular surface disease, in both of which vasculariza-
tion is prominent (Niederkorn, 2010). CD4 Th1 cells are the
main pathogenic T cells which induce corneal allograft rejection,
although recent evidence has implicated Th2 cells; intriguingly
there is a suggestion that IL-17A, whether derived from Th17
cells or from other sources, is necessary for allograft survival
(reviewed in Cunnusamy et al., 2010). The evidence for IP pre-
venting corneal graft rejection is therefore not strong, its main
effect probably being to blunt direct allorecognition. Perhaps the
most intriguing possibility is that the absence of a strong CD8+
T cell cytolytic alloresponse in orthotopic corneal graft rejection
(Boisgerault et al., 2009) may not simply be attributable to low lev-
els of donor MHC antigens, but that donor leukocytes migrating
to the host DLN, arrive there as “privileged” cells from a healthy
thrombospondin (TSP)-, RA-, and TGFβ-rich donor immunoreg-
ulatory microenvironment (Saban et al., 2010) and are more liable
to promote tolerance rather than immunity. The balance will be
decided by the level of inﬂammation and innate immunity at the
site of the graft and thus the degree of surgical manipulation and
associated trauma itself will inﬂuence the outcome. In addition,
corneal expression of immunoregulatory molecules such as FasL
and TRAIL help to promote this IP/TCT (Ferguson and Grifﬁth,
2007). One major contributor to the immunoregulatory microen-
vironment appears tobeDAF (CD55) expressedbybothdonor and
host corneal cells (Esposito et al., 2010). However, this is insufﬁ-
cient to fully prevent the indirect alloresponse, which continues to
fuel the rejection process.
Retinal transplants
Several attempts have been made to transplant retinal tissue
(Anosova et al., 2001) or cells (photoreceptor cells, West et al.,
2010; Gust and Reh, 2011; RPE cells, Tezel et al., 2007) to
repair damaged or degenerating retina (West et al., 2009), but
only occasionally has survival and, importantly neural inte-
gration, been reported (MacLaren et al., 2006). The erroneous
notion that ocular IP will promote acceptance of such grafts
has been exposed by the need for immunosuppression to assist
graft acceptance (West et al., 2010). Very recently, photoreceptor
transplantation, neural integration, and even evidence of visual
function in mice have been demonstrated, indicating the feasi-
bility of such an approach although information on the duration
of survival of the photoreceptors was not detailed (Pearson et al.,
2012). In a similar study, photoreceptor survival was found to
extend for 4 weeks after which there was progressive apoptosis
of the grafted cells in the absence of signiﬁcant inﬂammation.
Survival could be extended by prior transfection of the pre-
cursor photoreceptor cells with XIAP, an anti-apoptotic gene (Yao
et al., 2011).
Intraocular stem cell transplants have been used to encourage
retinal cell differentiation in the appropriate microenvironment,
but also to capitalize on the immunosuppressive properties of
certain cells, such as mesenchymal stem cells (MSCs). It is too
early to decide whether these approaches are fanciful, but systemic
immunosuppression is required to delay rejection of such grafts
even for a short time, and accepted grafts donot appear to integrate
with retinal neuronal circuits (Hill et al., 2009; West et al., 2010).
OCULAR INFECTIONS: LESSONS LEARNT FROM AIDS
Infectious uveitis is unusual in the absence of systemic immun-
odeﬁciency. Many infectious organisms such as Toxoplasma gondii
and herpes simplex virus, reside latently in privileged sites such
as the eye and brain (Kinchington et al., 2012); however, the rel-
ative sanctuary provided by these sites is still under some degree
of systemic immune control since it is not until the CD4 T cell is
disabled, as in untreated AIDS patients, that these organisms can
“reactivate” and replicate, thereby causing severe damage (Scholz
et al., 2003). Organisms include toxoplasma, mycobacteria, pneu-
mocystis, candida, and other fungi, and several herpes viruses
such as CMV, HSV, and HTLV-1. Such organisms survive and
persist but “hide” from the immune system by hijacking privilege
(Jones et al., 2006; Lepisto et al., 2007). Interestingly, the new phe-
nomenon of “immune recovery uveitis” in HAART-treated AIDS
patients indicates that once the eye’s guard is lowered, it is sus-
ceptible to immune-mediated damage (Jabs, 2011), thus revealing
that the privileged status of the eye is an active process requir-
ing continued maintenance. Immune-mediated damage in these
circumstances can also be the result of reactivated infection, thus
complicating the issue further (Moorthy et al., 2012).
These developments in the context of AIDS have rele-
vance for non-AIDS-associated infectious uveitis in immuno-
competent patients. For instance much of the sight-threatening
effects of infectious disease (including the full panoply of viral,
(myco)bacterial, parasitic, and fungal infections such as trachoma,
onchocerca, toxoplasmosis, herpes stromal keratitis in which there
can be extensive tissue damage), is caused by a robust or even
exaggerated immune response. Thus although the host survives,
blindness may be the cost. The corollary is also true, as evidenced
by the failure of IP in an aging immune system to protect against
the re-awakening of latent infectious disease, much of which was
contracted in the neonatal and early childhood years. Interestingly,
those rare fatal cases of CNSHSV infection in children appear to be
linked to a mutation in TLR3, providing an example from Nature
in which defective innate immunity tips the balance in this precar-
ious struggle between immunity and infection (Zhang et al., 2007;
Guo et al., 2011).
PRIVILEGE IN THE BALANCE – PARA-INFLAMMATION
It is clear from the above that ocular IP is a ﬁnely judged act which
can readily tip. This applies to many physiological processes and
Medzhitov (2008) described it neatly as para-inﬂammation when
considering the body’s response to predictable perturbations such
as aging.
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DEGENERATIVE RETINAL DISEASE AND THE OCULAR IMMUNE
RESPONSE
Removal of dead and dying cells is homeostatic tissue husbandry.
Ferguson has championed this process to explain systemic tol-
erance induced after io injection of antigen, and regards it as a
general phenomenon (Ferguson and Grifﬁth, 2007; Grifﬁth et al.,
2011). Dead-cell scavenging occurs throughout life, and depends
on innate immune mechanisms involving resident macrophage
and parenchymal cell activity. AMD is considered a disease
in which para-inﬂammatory mechanisms fail either for genetic
(defects in complement genes) or environmental (smoking, diet,
metabolic disturbance) or even chronic infective (chlamydia,
HSV) reasons (reviewed in Xu et al., 2009). AMD is character-
ized by the accumulation of waste products (drusen) presumably
from retinal photoreceptor cells, both inside (increased lipofuscin
accumulation) and below the RPE cell (Figure 4A), in part due to
impaired complement Factor H binding to sulfated glycosamino-
glycans (Clark et al., 2010). Resident F4/80+ macrophages and
DCs in the sub-RPE/choroid (Figure 1) assist in clearing drusen
(Forrester et al., 2010); however, when drusen accumulate, there
is deposition of complement components and other acute phase
proteins, leading to a low grade pro-inﬂammatory macrophage
response and eventual subretinal neovascularization (Skeie and
Mullins, 2009; Figure 4B). RPE cells normally produce anti-
angiogenic factors (pigment epithelial cell-derived factor, PEDF
and TSP), but can switch to produce pro-inﬂammatory fac-
tors such as VEGF, which promote wet AMD (Ablonczy et al.,
2009). Prior to this (aberrant) reparative angiogenic response
however, chronic age-related degenerative changes in the RPE
occur and atrophic (Guo et al., 2011) AMD ensues, possibly as
a consequence of a defect in intracellular microRNA regula-
tion via DICER1 (Kaneko et al., 2011). In fact recent evidence
suggests that whether AMD develops as the dry or wet form
reﬂects how the “privileged” retina responds to speciﬁc media-
tors. In dry AMD, DICER appears to act via induction of the
inﬂammasome through NLRP3 and secretion of IL-18, leading to
RPE cell death, the hallmark of geographic atrophy or dry AMD
(Tarallo et al., 2012). In contrast, cells which phagocytose drusen,
the characteristic waste product produced by the RPE cell, also
secrete increased amounts of IL-18 again through NLRP-mediated
activation of the inﬂammasome, but under these circumstances
IL-18 may protect against retinal angiogenic responses, the hall-
mark of wet AMD and the obverse of geographic atrophy (Doyle
et al., 2012). Thus it appears, in this speciﬁc instance, that IL-
18, which is constitutively produced by the RPE cell (Jiang et al.,
2001), acts as a regulator of RPE function and determines whether
the RPE cell succumbs to aging stress (para-inﬂammation) and
dies (geographic atrophy) while attempting to prevent an angio-
genic response to an increasing age-related pro-inﬂammatory
microenvironment.
The angiogenic response in AMD is similar to other intraoc-
ular angiogenic responses such as the neovascular membranes
which occur in low grade chronic uveitis, and may be promoted
by arginase+ macrophages, as opposed to immunoregulatory
(F4/80+)macrophages associatedwith IP. Thus IP can be breached
not only by severe overwhelming inﬂammatory disease, but
by chronic, low grade angiogenesis-associated inﬂammation as
in chronic uveitis and AMD. Moreover, pathological subreti-
nal neovascularization can be reversed by utilizing IP-promoting
properties of FasL (Roychoudhury et al., 2010) and it may also
be true that IL-18 produced by the RPE is a further IP-associated
mediator of a constitutive anti-angiogenic response (Jiang et al.,
2001; Doyle et al., 2012).
Thus there is a spectrum of responses from homeostasis and
health (intact IP) through aging and chronic disease (disabled IP)
to fulminant (infectious) retinal necrosis (absent IP). Much of this
activity is considered “auto-inﬂammatory” involving activation
of innate immune receptors on various subsets of macrophages,
but an adaptive immune response in AMD, involving lipid or
proteolipid antigen and CD1a may also contribute to AMD-like
disease (Hollyﬁeld et al., 2008). This has implications for potential
stem cell therapies currently being mooted for treatment of inher-
ited retinal disease, and even AMD, since the assumption that IP
protects intraocular stemcell inocula fromscrutiny by the immune
system is clearly not true. As discussed below for glaucoma, the
ultimate test of an immunological basis for AMD will depend
on whether an immunologically based therapy will modify the
disease.
GLAUCOMA AND RETINAL NERVE DAMAGE
Chronic open angle glaucoma is a disease where cellular waste
accumulates in the trabecular meshwork (aqueous drainage path-
way, Figure 1) and may initiate an inﬂammatory response (Wax,
2011). While the evidence for this is scanty, the outcome of
glaucoma is neuroretinal damage which, when mediated by the
amino acid glutamate, is accompanied by a prominent inﬂam-
matory response. Remarkably, however, the retinal response to
glutamate damage appears to be one of enhanced neuroprotec-
tion mediated by recruitment of myeloid-derived suppressor cells
(MDSCs) (London et al., 2011). Indeed glutamate has been shown
to have IP properties at least in the brain (Fallarino et al., 2010;
Hansen and Caspi, 2010). There is a need for good experimen-
tal models of glaucoma which truly reﬂect the human disease. A
popular current model involves thermal or hypertonic occlusion
of episcleral veins, thus preventing aqueous drainage. The associ-
ated raised intraocular pressure leads to ganglion cell damage in
which activated CD200R+ retinal microglia are implicated (Taylor
et al., 2011).
In addition to the need for a suitable model of experimental
glaucoma which would reﬂect the human disease, the com-
plex role of IP-mediating factors is revealed. In a spontaneous
model of glaucoma, the absence of sFasL, which is a cleavage
product of membrane bound FasL, was shown to be associated
with increased retinal ganglion cell death while administration of
sFasL to the same mice, protected them from damage (Gregory
et al., 2011).
The evidence for involvement of the immune system in glau-
coma is tenuous but suggestive. Numerous studies in humans both
of systemic factors and of ocular tissue obtained from patients,
show several features such as potential serum indicators of dis-
ease as well as signs of innate immune activation of glial cells
with increased expression of MHC class II and other activa-
tion markers (reviewed in Tezel, 2011). However, whether this is
genuine evidence for an adaptive immune response in glaucoma,
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FIGURE 4 | Age-related macular degeneration (AMD) occurs in two
forms: dry, atrophic damage to the retinal photoreceptor and RPE cells
with chronic progressive loss of visual acuity; and wet AMD in which
new vessels originating from the choroidal layer, penetrate the
basement membrane of the RPE cells and leak fluid or blood into the
subretinal space with rapid loss of vision. (A) Diagram of dry AMD
showing drusen under the RPE layer, and extensive atrophic damage to RPE
cells. (B) Diagram of wet AMD showing in-growth of new blood vessels into
the subretinal space, causing extensive destruction of RPE and photoreceptor
layers.
or simply an up-regulated innate immune response to damage
as occurs in para-inﬂammation, is a moot point. As for AMD,
the test will come when an immunologically based therapy shows
an effective protection against the progressive vision-destroying
consequences of glaucoma.
DIABETIC RETINOPATHY
Diabetic retinopathy (DR) is the fourth commonest cause of
world-wide blindness, potentially increasing as the epidemic of
diabetes expands (Suttorp-Schulten and Rothova, 1996). DR is
a microvascular endotheliopathy, affecting small capillaries and
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post-capillary venules leading to occlusion and expanding areas
of retinal ischemia (Grant et al., 2004; Busik et al., 2009; Bhat-
wadekar et al., 2010). Like aging, diabetes leads to increasing levels
of intravascular leukocyte activation and adhesion, contributing
to capillary occlusion (MacKinnon et al., 2004). This probably
involves platelet–monocyte interactions (Ogata et al., 2006) since
there is evidence that CCR5+CD11b+ monocytes are the cul-
prit leukocytes (Serra et al., 2012). Trapped monocytes, as well
as activated retinal microglial and other retinal cells are sources
of VEGF driven by HIF1α (Wang et al., 2010; You et al., 2010),
and activate retinal angiogenesis, producing the vision-destroying
late disease, proliferative DR (PDR). Thus, drugs such as statins
act not only on metabolic lipid pathways (Klein, 2010) but also
as inhibitors of leukocyte adhesion to ameliorate or delay dis-
ease (Greenwood and Mason, 2007) which has been conﬁrmed in
a model of DR (Serra et al., 2012). The ocular pathology is not
speciﬁc but reﬂects a general process, also affecting kidneys and
peripheral nerves; indeed direct effects on bone marrow-derived
hemopoietic stem cell precursors accounts for the poor overall
wound healing response in diabetes (Busik et al., 2009). PDR in
fact represents a last-ditch but misguided attempt by the retina to
repair itself.
An interesting convergence of dysregulated metabolism and
activation of immune cells has emerged through the discovery of
the succinate receptor (SUCNR1; reviewed in Ariza et al., 2012)
which is likely to impact on the pathogenesis of diabetes and its
complications. Succinate is a normal metabolite involved in the
citric acid cycle and, in times of stress, accumulates in the mito-
chondria and ﬁnds its way to the extracellular space through a
series of transporters and porins in the various cell membranes.
Extracellular succinate levels above a certain concentration acti-
vate SUCNR1 on immature DCs and macrophages and lead to
induction of the inﬂammasome via accumulation of HIF1α even
in normoxic conditions (Wen et al., 2012).
The SUCNR1 receptor is expressed in the retina, speciﬁcally
in the retinal ganglion cells and in the RPE cells and has been
identiﬁed as having a major role in angiogenesis in the develop-
ing retina and also possibly in the retinal ischemia associated with
DR (Sapieha et al., 2008). The role of immune cells, particularly
inﬂammatory macrophages in retinal angiogenesis is well-known
(Chen et al., 2012) and the possibility that succinate may facil-
itate, if not drive, theses responses in pathological conditions
such as diabetes and perhaps in inﬂammation generally is an
intriguing one.
WHEN PRIVILEGE IS DANGEROUS
Immune privilege allows the eye “to keep a clean house,” but may
compromise survival of the host, for instance through unchecked
growth of tumors or through uncontrolled viral replication in
the CNS.
INTRAOCULAR MELANOMA
The commonest primary tumor of the eye is melanoma but tumor
growth is slower than in other tissues and the risk of tumor spread
is less; ocular melanoma occurs in older patients and late metas-
tases are commoner than in cutaneous melanoma (Kujala et al.,
2003; Rigel et al., 2010). The mode of spread in part determines
metastatic risk, ocular melanoma spread being predominantly
hematogenous, while cutaneous melanoma risk is determined
by local invasive depth (Rigel et al., 2010). Unchecked growth
of non-ocular tumors correlates with immune suppression, also
described as a form of IP (Kandalaft et al., 2010), and ascribed
in ocular tumors to tumor-inﬁltrating Tregs (Mougiakakos et al.,
2010). IP-related mechanisms may not only allow active growth of
allogeneic tumors grafted intraocularly, but eventually facilitates
tumor metastasis, leading to death (Niederkorn, 1997). However,
experimental models of intraocular tumors do not precisely mir-
ror the condition in humans, in particular by the important fact
that the experiment necessarily requires breakdown of the ocu-
lar barrier which is the critical factor determining metastases in
humans. Despite or perhaps in the light of this caveat, it is some-
what surprising that intraocular melanomas in humans fail to
grow as rapidly as skin melanomas. The behavior of intraocu-
lar tumors is related to the density of intratumoral macrophages
(reviewed in Jager et al., 2011) and depends on their type and
angiogenic properties: ocular melanoma pathogenicity is predi-
cated on its vascularity both clinically and experimentally (Foss
et al., 1996; McKenna and Kapp, 2006) while removal of M2-
type macrophages almost completely prevents tumor growth (Ly
et al., 2010). It is interesting that IP of non-ocular tumors is also
attributed to vascularity and to VEGF expression (Kandalaft et al.,
2010). In addition, intratumoral macrophages may belong to
the myeloid-derived suppressor cells (MDSCs) variety (Natara-
jan and Thomson, 2010; Bronkhorst et al., 2011; Chioda et al.,
2011) and directly suppress anti-tumor T cell responses. These
tumor-IP related cells have been identiﬁed in the spleen as GM-
CSF-dependent, CD11b+Gr1lo/int myeloid cells (Dolcetti et al.,
2010; Ugel et al., 2012) and it is interesting to speculate whether
they are equivalent to the spleen F4/80+ macrophages identiﬁed
as potential mediators of ocular IP (see above). In contrast, in
other ocular tumors, at least experimentally, pro-inﬂammatory
macrophages promote tumor regression (McKenna and Chen,
2010) and are recruited from a population of CD11b+CD15+
granulocytic cells in the circulation (McKenna et al., 2009). How-
ever, these cells are associated with Treg induction and their
precise role is unclear. Interestingly, Tregs in some non-ocular
tumors may have a beneﬁcial effect by regulating MDSCs, reveal-
ing the complexity of cellular interactions within the tumor
microenvironment (Zhang et al., 2010). The “privileged” tumor
microenvironment may actually co-operate with ocular IP. How-
ever, while a synergistic “immunoregulatory” double-dose of IP
may be operative, tumor IP and ocular IP may alternatively cancel
each other out, allowing either an uncontrolled profound pro-
inﬂammatory immune response, with spontaneous regression of
the tumor and severe collateral intraocular inﬂammation, or a
super-suppressed, profoundly anergic anti-tumor response with
metastases and rapid extraocular spread (i.e., a failure of response).
The former is less likely than the latter but iswell-documented clin-
ically and experimentally (Knisely and Niederkorn, 1990; Shields
et al., 1999). In addition, several mechanisms exist for tumor
rejection or evasion by the immune system. In one series of
experiments, rejection of tumors in the mouse anterior cham-
ber of the eye was dependent on CD4+ T cells and TRAIL, the
same molecule which is considered to underpin ocular IP-related
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systemic immune tolerance (see above; Wang et al., 2003). A fur-
ther regulatory element in IP-mediated growth of intraocular
tumors is via the sympathetic nervous system which in one exper-
iment was seen to be closely linked to intraocular production of
TGFβ (Vega et al., 2009).
Not all intraocular tumors behave similarly even when derived
from similar cells: many follow the pattern of growth underpinned
by privileged immunity while others are rejected. Recently it has
been shown that a speciﬁc tumor in mice, Ad5E1 can follow
two patterns of rejection one of which involves severe rejection
and tumor necrosis mediated by IFNγ with severe destructive
bystander damage to the eye which is dependent on TNFα, while
the second pattern also leads to tumor rejection but there is mini-
mal ocular damage. In the latter case, tumor killing was mediated
by an arginase+ population of macrophages (Coursey et al., 2012).
Thus direct killing via CTLs or by different subsets of macrophages
appears to determine the outcome both for the tumor and for the
eye (for review, see McKenna and Chen, 2010). Similar cellular
diversity has been found in intraocular melanomas in humans
(Bronkhorst et al., 2012).
It can be seen from this discussion that the immune response
to ocular tumors hangs in the balance, as does the survival of
the host. This precarious condition is dictated by the strength
of the ocular IP effect vs the desirable but impaired, anti-tumor
response. For tumors arising in the eye such as melanoma, the
combined effect of these “privileged” responses is beneﬁcial both
to the eye and the host provided the tumor is contained within the
eye, but once it breaks free the desired systemic immune response
is inadequate to control the tumorwith fatal consequences inmany
cases.
PRIMARY INTRAOCULAR LYMPHOMA
The eye contains few B and T cells outside the vasculature, occa-
sional cells passing through the fenestrated walls of the uveal
vessels (Figure 1). Primary intraocular lymphoma is grouped with
CNS lymphoma, a rare extra-nodal variant of non-Hodgkin’s lym-
phoma (Algazi et al., 2009) arising from post-germinal center B
cells (Coupland et al., 2009) and occurs by seeding of privileged
sites by hemopoietic progenitor cells after variable lineage dif-
ferentiation. The precise location of the lymphoma predicts its
behavior with retinal lymphomas being aggressive and choroidal
lymphomas beingmore“indolent,”while iris and ciliary body lym-
phomas are very rare (Coupland and Damato, 2008; Mashayekhi
et al., 2012). This behavior may reﬂect the relative IP status of the
tissue, retina being likely to posses greater privilege than choroid,
perhaps determined by speciﬁc subsets of resident myeloid cells
(see Cells and Tissues).
Primary intraocular tumors may represent one aspect of “an
experiment of Nature.” The paradoxically beneﬁcial effect of Treg
cells (see above) in some tumors of the head and neck is clearly
demonstrated by the development of tertiary lymphoid structures
(TLS) surrounding the tumor. TLS express intense immunoreg-
ulatory activity directed toward reducing chronic inﬂammation,
a recognized poor prognostic sign, and have been likened to sites
of induced IP. Constitutive IP in the eye may behave like a “TLS”
to protect the host in cases of intraocular lymphomas but is a
dangerous strategy (Fridman et al., 2010).
However, due to the rarity of primary intraocular lymphoma,
their biology is poorly understood and animal models have not
been very informative so far, thus the call for multicenter studies
to investigate these tumors is timely (Chan et al., 2011).
CANCER-ASSOCIATED RETINOPATHY AND THE PARA-NEOPLASTIC
SYNDROME
Another experiment of Nature is revealed by cancer-associated
retinopathy (CAR). Retinal antigens aberrantly expressed in
extra-ocular tumors induce serum antibodies and T cell responses,
invoking a para-neoplastic syndrome of progressive retinal
degeneration and eventual blindness (Bazhin et al., 2007). Early
studies revealed that antigens such as the photoreceptor visual
cycle regulatory protein, recoverin,were responsible andmany fur-
ther retinal antigens including the potent autoantigen, IRBP (see
above) have been implicated (Bianciotto et al., 2010). These obser-
vations spawned more intense investigations into (auto)immune-
mediated causes of common retinal degenerations such as AMD,
and prompted much of the immunological studies which came in
the wake of knowledge concerning the role of innate immune
genes such as complement. Interestingly, an alternative the-
ory involving secretion of VEGF by the tumor and expression
of VEGFR1 by retinal neural and vascular cells has been pro-
posed to explain CAR syndrome which involves speciﬁcally
loss of pericytes and increased retinal vascular leakage (Cao and
Cao, 2010).
Cancer-associated retinopathy also provides insight into the
nature of ocular IP and supports the notion of immunological
ignorance (antigen sequestration) as one form of IP. However,
the discussion above clearly shows that “all roads lead to Rome”
and that ocular IP, just like immunological tolerance gener-
ally, is subject to many checkpoints. It is not intrinsically diff-
erent from other forms of immune tolerance (Matzinger and
Kamala, 2011).
CONCLUSION
Immune regulation/tolerance induction occurs primarily via cen-
tral and peripheral mechanisms. However, there is an evolving
understanding that the target tissue and its microenvironment
can also modify the immune response (Matzinger and Kamala,
2011) and how this develops depends on the nature and prop-
erties of the tissue. The eye provides an excellent paradigm for
the concept of tissue regulation of immune responses and how
the same “danger signals” might not be recognized in the eye
as they are, for instance, in the lung or skin. Thus, the violent
immune response to toxoplasma in the gut is much more subdued
in the eye, giving the parasite time to sequester itself from the
patrolling killer immune cells. However, the process is not failsafe
and when it fails, it fails gloriously, with irreparable damage to
ocular structures and loss of sight (e.g., HSV-induced acute retinal
necrosis).
The ocular immune response encapsulates the full range of
classical and non-classical immune responses and demonstrates
many featureswhich are reﬂected in other tissues, but eye tissues by
modifying these responses reveal unexpected and novel features,
which are relevant to immune responses generally. In addition,
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IP involvesmany recognized immunoregulatory processes, includ-
ing induction of Tregs, and is inducible and transferable. This
has therapeutic potential, particularly for devising ways to restore
tolerance in ocular inﬂammatory disease, and for preventing
rejection of cells and tissues, such as stem cells, currently being
considered for treatment of world-wide blinding diseases such
as AMD.
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